DOV Stresses “Residual Value” Of Bicifadine In Chronic Pain Despite Initial Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm had planned an NDA filing in the first half of 2007 for use of the non-opioid analgesic for chronic low back pain.
You may also be interested in...
DOV Out-Licenses Pain Candidate Bicifadine To XTL
XTL shifts bicifadine’s development away from “novel indications in acute and chronic pain” to neuropathic pain, firm says.
DOV Out-Licenses Pain Candidate Bicifadine To XTL
XTL shifts bicifadine’s development away from “novel indications in acute and chronic pain” to neuropathic pain, firm says.
DOV Revamps Phase III Trial Population For Bicifadine
An NDA submission for the chronic lower back pain agent, expected in the first half of 2007, is postponed.